After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

Fintel reports that on February 19, 2025, Cantor Fitzgerald downgraded their outlook for Supernus Pharmaceuticals ...

US CNS specialist Supernus Pharmaceuticals has announced that its Phase IIb study of SPN-820 in adults with ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

Cantor Fitzgerald downgraded Supernus (SUPN) to Neutral from Overweight with a price target of $36, down from $57.Discover the Best Stocks and ...

Supernus Pharmaceuticals (NASDAQ:SUPN) stock drops as depression candidate SPN-820 misses main goals in Phase 2b trial. Read more here.

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Stifel Nicolaus analyst Annabel Samimy maintained a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price ...